Sanofi Prepares Pentasaccharide NDA For Nov. Following Favorable Phase III

Patients treated with Sanofi-Synthelabo/Organon's pentasaccharide compound SR 90107 have 50% fewer venous thromboembolic events than those on enoxaparin (Aventis' Lovenox), Sanofi-Synthelabo reported at a meeting with the financial community in London Sept. 6.